Pfizer Inc. (NYSE:PFE) has begun testing an over-the-counter version of Lipitor, the blockbuster drug that has plumped up the pharmaceutical giant’s coffers for more than a decade. Pfizer Inc. (NYSE:PFE) stock performance was 2.22% in last session and finished the day at $32.69. Traded volume was 26,325,091 million shares in the last session and the average volume of the stock remained 26.27 million shares. The beta of the stock remained 0.69. Pfizer Inc. (NYSE:PFE) insider ownership is 0.02%. Pfizer Inc. (NYSE:PFE) stock opened at $32.65 in last session, and closed at $32.75, while the day range of PFE stock is $32.60-$32.95.The stock showed a positive weekly performance of 2.38%.
Merck & Co Inc (NYSE:MRK), provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health and consumer care products worldwide. It offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of many human disorders. Merck & Co., Inc. (NYSE:MRK) stock opened at $57.40, in last session and closed at $56.88, by loosed -0.32%.The 52 week range was $42.87-$57.46.Company’s market capitalization is $167.26 billion.
Teva Pharmaceutical Industries Ltd. (TEVA) got approval of the generic equivalent to Evista (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock gained 0.79% and finished the last session at $49.80.The EPS of the stock remained 1.49.Company’s market capitalization is $47.20 billion.
Peregrine Pharmaceuticals (NASDAQ:PPHM) On Mar. 4 announced the presentation of data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies at two upcoming Keystone Symposia to be held March 9-13, 2014. Bavituximab, the company’s lead immunotherapy candidate, is advancing in a Phase III SUNRISE trial for the treatment of second-line non-small cell lung cancer. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock opened the session at $1.99, and closed the session at $2.82.The 52 week range of the PPHM stock remained $1.11-$2.88 and the day range was $1.98-$2.88.